Targeted therapy: A new hope for thyroid carcinomas

Critical Reviews in Oncology/Hematology

Volumn 94, Issue 1, 2015, Pages 55-63

  Perri, Francesco ^a   Pezzullo, Luciano ^a   Chiofalo, Maria Grazia ^a   Lastoria, Secondo ^a   Di Gennaro, Francesca ^a   Scarpati, Giuseppina Della Vittoria ^b   Caponigro, Francesco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

Author keywords

Anaplastic; Follicular; Medullary; Papillary; Pathway; Radioiodine therapy; Targeted therapy; Thyroid carcinoma

Indexed keywords

AXITINIB; B RAF KINASE; BETA CATENIN; CABOZANTINIB; CARBOPLATIN; COMBRETASTATIN A4; DABRAFENIB; DOXORUBICIN; GEMCITABINE; IRINOTECAN; LEVOTHYROXINE; MITOGEN ACTIVATED PROTEIN KINASE; MOTESANIB; PACLITAXEL; PAZOPANIB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PLATINUM DERIVATIVE; PROTEIN KINASE B; PROTEIN RET; RADIOACTIVE IODINE; SELUMETINIB; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TRANSCRIPTION FACTOR PAX8; UNINDEXED DRUG; VANDETANIB; VEMURAFENIB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CARCINOGENESIS; CELL CYCLE ARREST; CONTINUOUS INFUSION; DIARRHEA; DIFFERENTIATED THYROID CANCER; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; ELECTROLYTE DISTURBANCE; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GENE MUTATION; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HEART DISEASE; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; METASTATIC MELANOMA; MOLECULAR BIOLOGY; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; ORAL MUCOSITIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RISK BENEFIT ANALYSIS; SIGNAL TRANSDUCTION; SOLID TUMOR; SURVIVAL TIME; THYROID CANCER; THYROID CARCINOMA; THYROID DISEASE; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; ANTAGONISTS AND INHIBITORS; CARCINOMA; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY; THYROID NEOPLASMS;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CARCINOMA; HUMANS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RET; SIGNAL TRANSDUCTION; THYROID NEOPLASMS;

EID: 84925943908     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2014.10.012     Document Type: Review

References (57)

1. Pacini F., Castagna M.G., Brilli L., Pentheroudakis G. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012, 23(Suppl. 7):vii110-vii119. ESMO Guidelines Working Group.
2. Kloos R.T., Eng C., Evans D.B., et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009, 19:565-612. American Thyroid Association Guidelines Task Force.
3. Neff R.L., Farrar W.B., Kloos R.T., Burman K.D. Anaplastic thyroid cancer. Endocrinol Metab Clin N Am 2008, 37:525-538.
4. Dean D.S., Gharib H. Epidemiology of thyroid nodules. Best Pract Res Clin Endocrinol Metab 2008, 22:901-911.
5. Cooper D.S., Doherty G.M., Haugen B.R., et al. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009, 19:1167-1214.
6. Shimaoka K., Schoenfeld D.A., DeWys W.D., Creech R.H., DeConti R. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985, 56:2155-2160.
7. Ain K.B., Egorin M.J., DeSimone P.A. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 2000, 10(7):587-594.
8. Schlumberger M., Sherman S.I. Approach to the patient with advanced differentiated thyroid cancer. Eur J Endocrinol 2012, 166:5-11.
9. Santoro M., Carlomagno F., Romano A., et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 1995, 267:381-383.
10. Elisei R., Cosci B., Romei C., et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 2008, 93:682-687.
11. Haugen B.R., Sherman S.I. Evolving approaches to patients with advanced differentiated thyroid cancer. Endocr Rev 2013, 34:439-455.
12. Tufano R.P., Teixeira G.V., Bishop J., Carson K.A., Xing M. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine 2012, 91:274-286.
13. Safavi A., Vijayasekaran A., Guerrero M.A. New insight into the treatment of advanced differentiated thyroid cancer. J Thyroid Res 2012, 2012:437569.
14. Santarpia L., Myers J.N., Sherman S.I., Trimarchi F., Clayman G.L., El-Naggar A.K. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma. Cancer 2010, 116:2974-2983.
15. Marques A.R., Espadinha C., Catarino A.L., et al. Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 2002, 87:3947-3952.
16. Segev D.L., Umbricht C., Zeiger M.A. Molecular pathogenesis of thyroid cancer. Surg Oncol 2003, 12:69-90.
17. Ringel M.D., Hayre N., Saito J., et al. Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res 2001, 61:6105-6111.
18. Souza E.C., Ferreira A.C., Carvalho D.P. The mTOR protein as a target in thyroid cancer. Expert Opin Ther Targets 2011, 15:1099-1112.
19. Kurihara T., Ikeda S., Ishizaki Y., et al. Immunohistochemical and sequencing analyses of the Wnt signaling components in Japanese anaplastic thyroid cancers. Thyroid 2004, 14:1020-1029.
20. Ito T., Seyama T., Mizuno T., et al. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res. 1992, 52:1369-1371.
21. Klein M., Vignud J.M., Hennequin V. Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in vivo. Surgery 2000, 128:1059-1066.
22. Carlomagno F., Vitagliano D., Guida T., et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002, 62:7284-7290.
23. Ciardiello F., Caputo R., Damiano V., et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003, 9:1546-1556.
24. Wells S.A., Gosnell J.E., Gagel R.F., et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010, 28:767-772.
25. Robinson B.G., Paz-Ares L., Krebs A., Vasselli J., Haddad R. Vandetanib (100mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010, 95:2664-2671.
26. Wells S.A., Robinson B.G., Gagel R.F., et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012, 30:134-141.
27. Leboulleux S., Bastholt L., Krause T., et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 2012, 13:897-905.
28. Nagilla M., Brown R.L., Cohen E.E. Cabozantinib for the treatment of advanced medullary thyroid cancer. Adv Ther 2012, 29:925-934.
29. Elisei R., Schlumberger M.J., Müller S.P., et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 2013, 10(31(29)):3639-3646.
30. Steven I., Sherman I., Cohen E.W. Efficacy of cabozantinib (Cabo) in medullary thyroid cancer (MTC) patients with RAS or RET mutations: results from a phase III study. J Clin Oncol 2011, 31. abstr number 6000.
31. Zoghlami A., Roussel F., Sabourin J.C., et al. BRAF mutation in papillary thyroid carcinoma: predictive value for long-term prognosis and radioiodine sensitivity. Eur Ann Otorhinolaryngol Head Neck Dis 2013, pii: S1879-7296(13)00071-9.
32. Elisei R., Ugolini C., Viola D., et al. BRAF (V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 2008, 93:3943-3949.
33. Kim K.B., Cabanillas M.E., Lazar A.J., et al. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAFV600E mutation. Thyroid 2013, [Epub ahead of print].
34. Adjei A.A., Cohen R.B., Franklin W., et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008, 26:2139-2146.
35. Hayes D.N., Lucas A.S., Tanvetyanon T., et al. Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res 2012, 18:2056-2065.
36. Ho A.L., Grewal R.K., Leboeuf R., et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med 2013, 368:623-632.
37. Rothemberg S.M., McFadden D.G., Palmer E., Daniels G.H., Wirth L.J. Re-differentiation of radioiodine-refractory BRAF V600E mutant thyroid carcinoma with dabrafenib: a pilot study. J Clin Oncol 2013, 31. abstract number 6025.
38. Cabanillas M.E., Holsinger F.C., Sturgis E.M., et al. Pharmacodynamic study of neoadjuvant vemurafenib (VEM) in patients (pts) with BRAF mutated, locally advanced papillary thyroid cancer (PTC). J Clin Oncol 2013, 31. abstract number TPS 6100.
39. Gupta-Abramson V., Troxel A.B., Nellore A., et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008, 26:4714-4719.
40. Kloos R.T., Ringel M.D., Knopp M.V., et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009, 27:1675-1684.
41. Capdevila J., Iglesias L., Halperin I., et al. Sorafenib in metastatic thyroid cancer. Endocr Relat Cancer 2012, 19:209-216.
42. Lam E.T., Ringel M.D., Kloos R.T., et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010, 28:2323-2330.
43. Brose M.S., Nutting C., Jarzab B., et al. Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: the phase III DECISION trial. J Clin Oncol 2013, 31. abstract number 4.
44. Savvides P., Nagaiah G., Lavertu P., et al. Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Thyroid 2013, 23:600-604.
45. Sweeney C.J., Chiorean E.G., Verschraegen C.F., et al. A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors. J Clin Oncol 2010, 28:4513-4520.
46. Carr L.L., Mankoff D.A., Goulart B.H., et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2010, 16:5260-5268.
47. Ravaud A., de la Fouchardière C., Asselineau J., et al. Efficacy of sunitinib in advanced medullary thyroid carcinoma: intermediate results of phase II THYSU. Oncologist 2010, 15:212-213.
48. Sherman S.I., Wirth L.J., Droz J.P., et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008, 359:31-42.
49. Schlumberger M.J., Elisei R., Bastholt L., et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 2009, 27:3794-3801.
50. Bible K.C., Suman V.J., Molina J.R., et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 2010, 11:962-972.
51. Bible K.C., Suman V.J., Menefee M.E., et al. A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. J Clin Endocrinol Metab 2012, 97:3179-3184.
52. Martin L.P., Kozloff M.F., Herbst R.S., et al. Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours. Br J Cancer 2012, 107:1268-1276.
53. Deshpande H.A., Gettinger S., Sosa J.A. Axitinib: the evidence of its potential in the treatment of advanced thyroid cancer. Core Evid 2010, 4:43-48.
54. Sosa J.A., Balkissoon J., Lu S.P., et al. Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer. Surgery 2012, 152:1078-1087.
55. De la Fouchardiere C., Massicotte M.H., Borget I., et al. Sequential TKI treatments for iodine-refractory differentiated thyroid carcinomas. J Clin Oncol 2013, 31. abstract number 6092.
56. Mologni L., Redaelli S., Morandi A., Plaza-Menacho I., Gambacorti-Passerini C. Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase. Mol Cell Endocrinol 2013, 377:1-6.
57. Sherman E.J., Ho A.L., Fury M.G., et al. Phase II study of everolimus and sorafenib for the treatment of metastatic thyroid cancer. J Clin Oncol 2013, 31. abstr 6024.